Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Lung Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood
Overview
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.
Detailed description
OBJECTIVES:
* Examine the mutational status of the EGFR pathway in tumor and blood samples from patients with lung cancer. * Correlate the EGFR pathway mutations in these samples with clinical outcomes of these patients.
OUTLINE: Archived tumor tissue and blood samples are analyzed via PCR to detect EGFR pathway mutations in DNA.
Primary outcome measures
- Mutational status of the EGFR pathway [Time frame: up to 1 year]
Eligibility criteria
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed lung cancer
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- May have received prior EGFR inhibitors
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- University of California Davis Cancer Center — Sacramento
Identifiers
NCT: NCT00899405 · 225287 · UCD-155 · UCD-200412410 · CDR0000583056 · UCDCC155